NCT02852850|UnknownDMC
In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis
Loading search results
In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis
Sponsor study identifier
observational
30
1 country
1
Study Start
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
Not reported
Date not reportedMolecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
July 29, 2016
Actual (reported)August 2, 2016
Actual (reported)June 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The number of specific fluorescence signal of mTNF+ cells in patients with UC
30 months
Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
Patients with active ulcerative colitis will receive infliximab antibody therapy.
Department of Gastroenterology, Qilu Hospital, Shandong University
Jinan, Shandong, 250012, China
Yanqing Li, MD,PHD
Qilu Hospital of Shandong University
First Submitted
July 29, 2016
First Posted
August 2, 2016
Study Start
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2018
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 17, 2016
Record last verified: 2016-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: